-
Mashup Score: 2
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Source: MobiHealthNewsCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Online Event - 1 year(s) ago
Already Registered? Click HereAntibody discovery is a time-intensive process that traditionally can take up to 12 months to identify a panel of potential candidates. This discovery process can be costly if those candidates are not well-behaved and fail in downstream in vitro and in vivo functionality and efficacy studies. These headaches can be avoided by employing platforms that provide rapid,…
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet-
Join us LATER TODAY for our free webinar sponsored by @CRiverLabs Our guests will take us through case studies on CD47, TFR1, and SIRPa #antibody discovery programs leveraging the Distributed Bio 's antibody discovery technology. Register now: https://t.co/9J3jmYm6EG https://t.co/4rimzI18yM
-
-
Mashup Score: 2Online Event - 1 year(s) ago
Already Registered? Click HereAntibody discovery is a time-intensive process that traditionally can take up to 12 months to identify a panel of potential candidates. This discovery process can be costly if those candidates are not well-behaved and fail in downstream in vitro and in vivo functionality and efficacy studies. These headaches can be avoided by employing platforms that provide rapid,…
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet-
Don't miss our free webinar TOMORROW sponsored by @CRiverLabs Our presenters will take us through case studies on CD47, TFR1, and SIRPa #antibody discovery programs leveraging the Distributed Bio 's antibody discovery technology. Register here: https://t.co/9J3jmYmEue https://t.co/Vo3MoISp90
-
-
Mashup Score: 0Online Event - 1 year(s) ago
Already Registered? Click HereAntibody discovery is a time-intensive process that traditionally can take up to 12 months to identify a panel of potential candidates. This discovery process can be costly if those candidates are not well-behaved and fail in downstream in vitro and in vivo functionality and efficacy studies. These headaches can be avoided by employing platforms that provide rapid,…
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet-
Join us Wednesday for our free webinar sponsored by @CRiverLabs Our presenters will take us through case studies on CD47, TFR1, and SIRPa #antibody discovery programs leveraging the Distributed Bio's antibody discovery technology. Register here: https://t.co/9J3jmYm6EG https://t.co/tgKmS6wwvE
-
-
Mashup Score: 5Current issue: Trends in Immunology - 1 year(s) ago
Spiking SARS-CoV-2 antiviral immunity in the respiratory tractThe COVID-19 pandemic enabled the successful launch of mRNA-based vaccines that, when given intramuscularly, elicit spike-specific antibodies and prevent severe disease, but do not promote mucosal immunity. New data suggest how to boost systemic immunity and elicit pulmonary immunity in a way that more effectively controls infection…
Source: www.cell.comCategories: Allergy-Immunology, Latest HeadlinesTweet-
Read the Feb issue @TrendsImmuno ! #SARSCoV2, #Blackdeath, #cytokine release syndrome, type 2 #diabetes, tolerogenic dendritic cells, #RAG scanning & #antibody diversity, #GATA6 cavity #macrophages in infection & injury, & more!! https://t.co/UbIxpvkNNP https://t.co/uC2JgNdTqN
-
-
Mashup Score: 0AI-Based Strategy Boosts High-Affinity Antibody Drug Discovery - 1 year(s) ago
Artificial intelligence aids the discovery of super tight-binding antibodies which could accelerate the development of new antibody drugs.
Categories: Future of Medicine, Latest HeadlinesTweet-
#AI Based Strategy Boosts High-Affinity Antibody Drug Discovery Researchers used the pipeline (called RESP) to identify a new antibody that binds a major #cancer target 17-fold tighter than an existing #antibody drug. Read more: https://t.co/iwdcvdYoI6 #artificialintelligence https://t.co/CAIiaTYWPr
-
-
Mashup Score: 0Online Event - 1 year(s) ago
Already Registered? Click HereAntibody discovery is a time-intensive process that traditionally can take up to 12 months to identify a panel of potential candidates. This discovery process can be costly if those candidates are not well-behaved and fail in downstream in vitro and in vivo functionality and efficacy studies. These headaches can be avoided by employing platforms that provide rapid,…
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet-
Register for our free upcoming webinar sponsored by @CRiverLabs Our presenters will take us through case studies on CD47, TFR1, and SIRPa #antibody discovery programs leveraging the Distributed Bio 's antibody discovery technology. Register here: https://t.co/9J3jmYm6EG https://t.co/liJ29G1RBE
-
-
Mashup Score: 1Online Event - 1 year(s) ago
Already Registered? Click HereAntibody discovery is a time-intensive process that traditionally can take up to 12 months to identify a panel of potential candidates. This discovery process can be costly if those candidates are not well-behaved and fail in downstream in vitro and in vivo functionality and efficacy studies. These headaches can be avoided by employing platforms that provide rapid,…
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet-
Register for our free upcoming webinar sponsored by @CRiverLabs Our presenters will take us through case studies on CD47, TFR1, and SIRPa #antibody discovery programs leveraging the Distributed Bio 's antibody discovery technology. Register here: https://t.co/9J3jmYm6EG https://t.co/B3mqY8yqWw
-
-
Mashup Score: 0Online Event - 1 year(s) ago
Already Registered? Click HereAntibody discovery is a time-intensive process that traditionally can take up to 12 months to identify a panel of potential candidates. This discovery process can be costly if those candidates are not well-behaved and fail in downstream in vitro and in vivo functionality and efficacy studies. These headaches can be avoided by employing platforms that provide rapid,…
Source: www.workcast.comCategories: Future of Medicine, Latest HeadlinesTweet-
Register for our free upcoming webinar sponsored by @CRiverLabs Our presenters will take us through case studies on CD47, TFR1, and SIRPa #antibody discovery programs leveraging the Distributed Bio 's antibody discovery technology. Register here: https://t.co/9J3jmYm6EG https://t.co/eQajE5ot4e
-
-
Mashup Score: 0
The longitudinal SARS-CoV-2-specific antibody response in human milk of lactating women receiving an mRNA-based booster vaccine indicates that both homologous and heterologous boosters enhance SARS-CoV-2-specific antibodies in human milk.
Source: NatureCategories: Infectious Disease, Latest HeadlinesTweet-
🍼 We know breast milk contains #SARSCoV2-specific antibodies after vaccination, which decrease several months later. But do booster doses restore #antibody levels, potentially offering prolonged passive immunity for the baby? Find out in @CommsBio: 📎 https://t.co/G8r4zsXytu https://t.co/iZ3zHOkaC4
-
.@AIONLabs launches second #startup focused on #AI-enabled #antibody design | #drugdiscovery https://t.co/mfn2WbUFVn